Content about GlaxoSmithKline

September 1, 2011
GSK announces VP sales Clark Brown departure

GlaxoSmithKline on Thursday announced that 25-year veteran Clark Brown, VP sales at GSK Consumer Healthcare, will be leaving the organization effective Sept. 2.

PITTSBURGH — GlaxoSmithKline on Thursday announced that 25-year veteran Clark Brown, VP sales at GSK Consumer Healthcare, will be leaving the organization effective Sept. 2.

“Clark has been a valuable team member throughout his many years with GSK, and his passion and effective leadership of the U.S. consumer sales team has been critical to the success of our business,” stated Colin Mackenzie, president GSK Consumer Healthcare North America.

August 15, 2011
Study: Investigational GSK, Impax drug reduces Parkinson's symptoms

Patients taking an experimental treatment for Parkinson's disease experienced greater reduction in symptoms than those taking standard therapies, according to results of a late-stage clinical trial.

HAYWARD, Calif. — Patients taking an experimental treatment for Parkinson's disease experienced greater reduction in symptoms than those taking a drug already on the market, according to results of a late-stage clinical trial.

August 11, 2011
GSK, XenoPort file sNDA for Horizant

Drug makers GlaxoSmithKline and XenoPort are seeking expanded approval for their restless legs syndrome treatment.

LONDON — Drug makers GlaxoSmithKline and XenoPort are seeking expanded approval for their restless legs syndrome treatment.

The drug makers this week announced the submission of a supplemental new drug application to the Food and Drug Administration, requesting approval for Horizant (gabapentin enacarbil) extended-release tablets as a treatment for postherpetic neuralgia, a nerve pain that commonly is seen in patients with shingles. GSK submitted the sNDA on behalf of the two companies.

August 9, 2011
GSK names new chief marketing officer

GlaxoSmithKline Consumer Healthcare on Monday named John Graham chief marketing officer for Consumer Healthcare, North America.

PITTSBURGH — GlaxoSmithKline Consumer Healthcare on Monday named John Graham chief marketing officer for Consumer Healthcare, North America.

August 4, 2011
Stiefel seeks FDA approval for tazarotene foam

GlaxoSmithKline company Stiefel announced it is seeking approval for a facial acne treatment in patients ages 12 years and older.

RESEARCH TRIANGLE PARK, N.C. — GlaxoSmithKline company Stiefel announced it is seeking approval for a facial acne treatment in patients ages 12 years and older.

Stiefel said it has submitted a new drug application to the Food and Drug Administration for tazarotene foam. Tazarotene foam is subject to evaluation and approval by the regulatory authorities before it can be made available to physicians for prescribing to their appropriate patients, Stiefel said.

July 28, 2011
GSK expects to divest noncore OTC brands by late 2011, company says

GlaxoSmithKline expects to close the deal on the divestiture of several over-the-counter brands that were identified in April, the company stated Tuesday as part of its second-quarter earnings results.

PHILADELPHIA — GlaxoSmithKline expects to close the deal on the divestiture of several over-the-counter brands that were identified in April, the company stated Tuesday as part of its second-quarter earnings results.

"The divestment of noncore OTC assets in the [United States] and Europe will further aid our strategy to accelerate growth and increase the focus of our Consumer Healthcare business," GSK stated. "We are making progress to divest these products by late 2011, subject to realizing appropriate value for shareholders."

July 25, 2011
Watson seeks to market generic Jalyn

Watson Pharmaceuticals is hoping to be the first to market a generic version of a GlaxoSmithKline drug for men with an enlarged prostate, Watson said.

PARSIPPANY, N.J. — Watson Pharmaceuticals is hoping to be the first to market a generic version of a GlaxoSmithKline drug for men with an enlarged prostate, Watson said.

Watson announced that it filed a regulatory approval application to market a generic version of GSK’s Jalyn (dutasteride and tamsulosin hydrochloride) capsules, a treatment for symptomatic benign prostatic hyperplasia in men with enlarged prostates.

July 25, 2011
Wellness drives sales in digestives, probiotics

Sales in the digestives aisle going forward look positive, especially as an aging population begins paying closer attention to healthy diets, including the right amount of dietary fiber to keep things “regular” and supplementation with probiotics for overall digestive health. 


Sales in the digestives aisle going forward look positive, especially as an aging population begins paying closer attention to healthy diets, including the right amount of dietary fiber to keep things “regular” and supplementation with probiotics for overall digestive health. 


July 22, 2011
Perrigo to market store-brand smoking-cessation gum

Perrigo on Thursday announced that it has received approval from the Food and Drug Administration to market a cinnamon-flavored, over-the-counter coated nicotine polacrilex gum USP in 2-mg and 4-mg strengths.

ALLEGAN, Mich. — Perrigo on Thursday announced that it has received approval from the Food and Drug Administration to market a cinnamon-flavored, over-the-counter coated nicotine polacrilex gum USP in 2-mg and 4-mg strengths.

The product will be marketed under store-brand labels and is comparable with GlaxoSmithKline's Nicorette Cinnamon Surge coated gum, a stop-smoking aid.

July 15, 2011
FDA approves Dr. Reddy’s generic anticoagulant drug

The Food and Drug Administration has approved a generic anticoagulant drug made by Dr. Reddy’s Labs and Alchemia.

HYDERABAD, India — The Food and Drug Administration has approved a generic anticoagulant drug made by Dr. Reddy’s Labs and Alchemia.

Dr. Reddy’s and Brisbane, Australia-based Alchemia announced the FDA approval of fondaparinux sodium injection in the 2.5 mg/0.5 mL, 5 mg/0.4 mL, 7.5 mg/0.6 mL and 10 mg/0.8 mL strengths. Alchemia owns the patents covering the process for synthesis of fondaparinux.

July 11, 2011
Amneal launches three generic liquid drugs

Generic drug maker Amneal has launched three new liquid drugs, the company said Monday.

BRIDGEWATER, N.J. — Generic drug maker Amneal has launched three new liquid drugs, the company said Monday.

July 11, 2011
FDA approves combo vaccine for elderly patients

The Food and Drug Administration has approved a vaccine for preventing tetanus, diphtheria and whooping cough in elderly patients.

SILVER SPRING, Md. — The Food and Drug Administration has approved a vaccine for preventing tetanus, diphtheria and whooping cough in elderly patients.

The FDA announced the approval of GlaxoSmithKline’s Boostrix, a single-dose booster shot described as the first vaccine approved for preventing all three diseases in patients ages 65 years and older.

July 11, 2011
Stiefel introduces Revaleskin-branded anti-aging treatment

Stiefel, a GlaxoSmithKline company, has expanded its Revaleskin family of products with its new Revaleskin Illuminesse Brightening Complex.

RESEARCH TRIANGLE PARK, N.C. — Stiefel, a GlaxoSmithKline company, has expanded its Revaleskin family of products with its new Revaleskin Illuminesse Brightening Complex.

Made with CoffeeBerry whole fruit extract, the anti-aging treatment is designed to provide antioxidants to neutralize against free radical damage caused by UV exposure, which can result in uneven skin tone, mild age spots and the loss of brightness and youthful luminosity of the skin. For maximum sun protection, the formula should be used in addition to sunscreen, not as a substitute. 

June 21, 2011
Watson seeks to commercialize generic Avodart

Watson subsidiary Watson Labs is seeking approval for a drug designed to treat symptomatic benign prostatic hyperplasia in men with an enlarged prostate.

PARSIPPANY, N.J. — Watson subsidiary Watson Labs is seeking approval for a drug designed to treat symptomatic benign prostatic hyperplasia in men with an enlarged prostate.

The company filed an abbreviated new drug application to market dutasteride capsules in the 0.5-mg strength. The drug is a generic version of Avodart, which is made by GlaxoSmithKline.

June 20, 2011
Three’s not a crowd: Top antacids hold their own


Good things come in three — like the three antacids that for the 52 weeks ended April 17 collectively generated more than $118 million in sales on top of the sales base they had established in the year-ago period.



Good things come in three — like the three antacids that for the 52 weeks ended April 17 collectively generated more than $118 million in sales on top of the sales base they had established in the year-ago period.


June 14, 2011
Report: GSK brands on sales block peak interest

GlaxoSmithKline has garnered strong interest in its portfolio of legacy brands that were placed on the sales block earlier this year, according to a Reuters report published Tuesday. And that interest is likely to pick up in the coming months, GSK CEO Andrew Witty told reporters during a meeting of pharmaceutical industry executives.

BRUSSELS — GlaxoSmithKline has garnered strong interest in its portfolio of legacy brands that were placed on the sales block earlier this year, according to a Reuters report published Tuesday. And that interest is likely to pick up in the coming months, GSK CEO Andrew Witty told reporters during a meeting of pharmaceutical industry executives.

The interest is coming from both established consumer healthcare companies, as well as private equity houses, the report noted.

June 13, 2011
GSK, Valeant receive FDA approval for Potiga

The Food and Drug Administration has approved a new drug for epilepsy made by GlaxoSmithKline and Valeant Pharmaceuticals International, the drug makers said Monday.

RESEARCH TRIANGLE PARK, N.C. — The Food and Drug Administration has approved a new drug for epilepsy made by GlaxoSmithKline and Valeant Pharmaceuticals International, the drug makers said Monday.

The FDA approved Potiga (ezogabine) tablets for the treatment of partial-onset seizures in patients ages 18 years and older.

June 10, 2011
H1N1 flu variant may be resistant to certain treatments

A new strain of swine flu has emerged that appears somewhat resistant to flu drugs, according to published reports.

NEW YORK — A new strain of swine flu has emerged that appears somewhat resistant to flu drugs, according to published reports.

Reuters reported that scientists in Australia and Singapore had found a variant of the H1N1 flu that showed some resistance to Roche’s Tamiflu (oseltamivir phosphate) and GlaxoSmithKline’s Relenza (zanamivir), though drug maker BioCryst currently is developing a drug called peramivir, to which the strain was not resistant.

May 23, 2011
Pump up the iron


It’s not often a niche brand manufacturer attempts to resuscitate what has been for years a commoditized category. But that’s exactly what Meda Consumer Healthcare will be attempting to do with iron — establish a good/better/best proposition to a supplemented category best defined as mediocre.


It’s not often a niche brand manufacturer attempts to resuscitate what has been for years a commoditized category. But that’s exactly what Meda Consumer Healthcare will be attempting to do with iron — establish a good/better/best proposition to a supplemented category best defined as mediocre. For the 52 weeks ended April 16, mineral supplement sales were down 3.3% to $534 million across food, drug and mass (including Walmart), according to Nielsen Group data.


May 19, 2011
Avandia to be available only by mail order in November, FDA asserts

A controversial GlaxoSmithKline drug for treating Type 2 diabetes no longer will be available through retail pharmacies as of Nov. 18, the Food and Drug Administration announced Wednesday.

SILVER SPRING, Md. — A controversial GlaxoSmithKline drug for treating Type 2 diabetes no longer will be available through retail pharmacies as of Nov. 18, the Food and Drug Administration announced Wednesday.

May 11, 2011
Perrigo to settle litigation related to generic Cutivate

Drug maker Perrigo has reached a licensing agreement with Nycomed US that will allow it to launch a generic treatment for dermatitis in 2012, the company said.

ALLEGAN, Mich. — Drug maker Perrigo has reached a licensing agreement with Nycomed US that will allow it to launch a generic treatment for dermatitis in 2012, the company said.

Perrigo said it agreed to settle all Hatch-Waxman litigation relating to its generic version of Cutivate (fluticasone) lotion with Nycomed, allowing it to launch under a licensing agreement in September 2012.

Cutivate is used to treat dermatitis in patients ages 1 year and older and had sales of about $50 million during the 12-month period ended in February, according to Wolters Kluwer.

April 27, 2011
OTC Perspectives to honor top marketers

OTC Perspectives magazine on Tuesday named its third annual list of "Top OTC/HBA Marketers of the Year."

VERONA, N.J. — OTC Perspectives magazine on Tuesday named its third annual list of "Top OTC/HBA Marketers of the Year."

Marketers of over-the-counter products and health-and-beauty aids will be honored at a celebratory luncheon on May 10 during the OTC/HBA National Conference.

April 26, 2011
Lamictal XR receives FDA approval as monotherapy

The Food and Drug Administration has approved a new indication for an epilepsy drug made by GlaxoSmithKline, the drug maker said Monday.

RESEARCH TRIANGLE PARK, N.C. — The Food and Drug Administration has approved a new indication for an epilepsy drug made by GlaxoSmithKline, the drug maker said Monday.

April 21, 2011
GSK applauds agreement to support global preparedness against pandemic influenza

Companies that make vaccines, drugs and diagnostic tests for influenza will become key stakeholders in the World Health Organization’s Global Influenza Surveillance Network under an agreement reached at the Open Ended Working Group that WHO coordinated to support global preparedness for a future influenza pandemic.

LONDON — Companies that make vaccines, drugs and diagnostic tests for influenza will become key stakeholders in the World Health Organization’s Global Influenza Surveillance Network under an agreement reached at the Open Ended Working Group that WHO coordinated to support global preparedness for a future influenza pandemic.

April 21, 2011
GSK, Valeant respond to CRL for ezogabine

GlaxoSmithKline and Valeant last week responded to the Food and Drug Administration's complete response letter for the companies' investigational anti-epileptic drug.

LONDON — GlaxoSmithKline and Valeant last week responded to the Food and Drug Administration's complete response letter for the companies' investigational anti-epileptic drug.